The state of Missouri currently has 6 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: Study Site, Saint Louis, Missouri
Conditions: Hereditary Angioedema (HAE)
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: Study Site, Saint Louis, Missouri
Conditions: Hereditary Angioedema (HAE)
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
Recruiting
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
07/09/2025
Locations: KalVista Investigative Site, Saint Louis, Missouri
Conditions: Hereditary Angioedema
A Phase 2 in Adult Subjects With Hereditary Angioedema
Recruiting
A Phase 2 in Adult Subjects with Hereditary Angioedema
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Hereditary Angioedema (HAE)
A Study of Navenibart in Participants With Hereditary Angioedema
Recruiting
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: Site 10, St. Louis, Missouri
Conditions: Hereditary Angioedema (HAE)
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
04/16/2025
Locations: Study Site, Saint Louis, Missouri
Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III